Please login to the form below

Not currently logged in
Email:
Password:

Orbactiv

This page shows the latest Orbactiv news and features for those working in and with pharma, biotech and healthcare.

Actavis gets FDA nod for new antibiotic

Actavis gets FDA nod for new antibiotic

dalbavancin) and The Medicine Company's Orbactiv (oritavancin).

Latest news

  • Antibiotics among 7 new drugs backed by EMA Antibiotics among 7 new drugs backed by EMA

    The Medicines Company’s Orbactiv and Cubist’s Sivextro set for European approval. ... Orbactiv and Sivextro are already recommended by the US FDA to treat these forms of infections.

  • FDA backs Cubist's antibiotic Zerbaxa FDA backs Cubist's antibiotic Zerbaxa

    In addition to Sivextro, the agency also gave a green light this year to Durata Therapeutics' Dalvance (dalbavancin) - recently acquired by Actavis - and The Medicines Company's Orbactiv (oritavancin).

  • Actavis buys infectious disease specialist Durata Actavis buys infectious disease specialist Durata

    Cubicin (daptomycin) and Sivextro (tidezolid) and The Medicine Company's Orbactiv (oritavancin) in the ABSSSI category.

  • FDA approves antibacterial skin drug Orbactiv FDA approves antibacterial skin drug Orbactiv

    US regulator authorises Medicines Company's treatment for ABSSSI. The Food and Drug Administration has approved antibacterial drug Orbactiv (oritavancin) to treat adults with acute bacterial skin and skin structure infections ... Orbactiv is the third

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics